Back

Six-month results from the ATHENS-HF FIH trial of the Adona Medical adjustable, biatrial pressure sensing interatrial shunt

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: From classic drugs to new interventions in heart failure Devices for Autonomic Modulation Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Karl-Philipp Rommel

University Medical Centre of the Johannes Gutenberg University, Mainz (Germany)

5 More presentations in this session

Presentation thumbnail
Efficacy and safety of guideline-directed medical therapies according to background use of digoxin: Insights from RALES, PARADIGM-HF, and DAPA-HF
Doctor R. Helseth (Boston, US)
Abstract Slides Video
Presentation thumbnail
Back to the future - digitalis therapy reloaded? The suitability for digitoxin treatment in a real-world, outpatient heart failure patient cohort
Miss K. Czurko (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Role of ferric carboxymaltose supplementation on comprehensive geriatric assessment in elderly patients with chronic heart failure
Doctor M. Scarcelli (Catanzaro, IT)
Abstract Slides Video
Presentation thumbnail
Contemporary characteristics and treatment patterns of patients with HFmrEF and HFpEF in Germany. A cross-sectional survey.
Doctor A. Michel (Basel, CH)
Abstract Slides Video
Presentation thumbnail
The positive effect of sacubitril/valsartan therapy on QRS width and QTC interval on electrocardiogram in heart failure patients with reduced ejection fraction
Doctor P. Kekovic (Prokuplje, RS)
Abstract Slides Video

Access the full session

Session thumbnail
From classic drugs to new interventions in heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Session
Late breaking clinical trials: devices
thumbnail
Congress Session
The march of the devices in heart failure
thumbnail
Congress Session
Innovative approaches in the management of patients with heart failure with reduced ejection fraction (HFrEF) in the era of guideline-directed medical therapy (GDMT)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources